Form 8-K - Current report:
SEC Accession No. 0001213900-25-062803
Filing Date
2025-07-10
Accepted
2025-07-10 16:30:31
Documents
12
Period of Report
2025-07-07
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0248503-8k_relmada.htm   iXBRL 8-K 25556
  Complete submission text file 0001213900-25-062803.txt   190727

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE rlmd-20250707.xsd EX-101.SCH 3011
3 XBRL LABEL FILE rlmd-20250707_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE rlmd-20250707_pre.xml EX-101.PRE 22356
14 EXTRACTED XBRL INSTANCE DOCUMENT ea0248503-8k_relmada_htm.xml XML 3694
Mailing Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134
Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39082 | Film No.: 251116613
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)